Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
E. Efstathiou reports on study results presented on prostate cancer at ASCO 2019. She explains the benefits of adding hormonal agents early in the disease spectrum, and discusses the prospect of combinatorial strategies based on biomarkers selection.
- LBA2 / Overall survival (OS) results of ENZAMET (ANZUP 1304) trial
- Abstract 5006 / First results from TITAN trial
- Abstract 5008 / Alliance A031201: A phase III trial in mCRPC
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
